louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06109220: Treatment of Knee Osteoarthritis (KOA) by Injection of Autologous Adipose-derived Vascular Matrix Components (SVF) Into Joint Cavity
Official title: Clinical Study on the Safety and Efficacy of Intrarticular Injection of Autologous Adipose-derived Vascular Matrix Components (SVF) in the Treatment of Knee Osteoarthritis (KOA)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Knee Osteoarthritis
Keywords: Stromal vascular fraction
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2023-10-31
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to analyze and study the efficacy and safety of autologous adipose-derived vascular matrix components (SVF) in patients with knee osteoarthritis before and after treatment through clinical evaluation, radiation index, and metabolic index comparison between plasma and irrigation solution before and after SVF injection.


Eligibility criteria: Inclusion Criteria:

* The age range is 20-70 years old
* Patients with unilateral or bilateral knee degenerative inflammation (KOA) with Kellgren-lawrence rating of level 3 or lower
* The physical health status is mainly in the ASA grade Ⅰ, Ⅱ and Ⅲ
* Subjects had no active tumors, no active inflammation, no treponema pallidum, HIV, hepatitis B virus, or hepatitis C virus
* The subject shall provide the physical examination report of knee X-ray examination, MRI examination and other items

Exclusion Criteria:

* Patients with nonunion or displaced fractures around defective cartilage
* Pregnant or lactating women
* Autoimmune disease
* Subjects with diabetes (exceptions are patients whose blood sugar levels remain within the normal range and diabetes has not caused other complications)
* The patients had severe neurological diseases affecting the evaluation of postoperative results

Primary outcomes:
measure: T2 mapping
timeFrame: 24 months after the first SVF injection into the knee cavity
Secondary outcomes:
measure: Western Ontario and McMaster Universities Arthritis Index (WOMAC)
timeFrame: 24 months after the first SVF injection into the knee cavity
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hospital
state: Shannxi
Study officials:
References:
Clinical trial NCT03757520: Evaluation of Text Neck Syndrome and Hand Grip Force in Smart Phone Addiction Among Students of Jazan University
Official title: Evaluation of Text Neck Syndrome and Hand Grip Force in Smart Phone Addiction Among Students of Jazan University
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain, Back
Neck Pain
Postural; Strain
Myofascial Pain Syndrome
Lead sponsor: University of Jazan
Sponsor class: OTHER_GOV
First posted: 2018-11-29
Enrollment: 600
Sex: ALL
Minimum age (years): 19
Maximum age (years): 26
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Intervention model description: According two Smartphone Addiction Proneness Scale (SAPS) the subjects will be divided into two groups: Regular user group with SAPS score 39 or less. Heavy user group with SAPS score 40 or more.

we have two variables to be assessed:

1. Pain pressure threshold for two muscles (upper fiber of trapezius and sternocleidomastoid muscle)
2. Hand grip force
Primary purpose: DIAGNOSTIC

Brief summary: This study will be conducted in the Department of physical therapy, College of Applied Medical Sciences,Jazan University, to investigate text neck syndrome and hand grip force in smart phone addiction among students of jazan university

Detailed description: Four hundreds students with age 19 to 26 years old, and right dominant hand, will be recruited from the College of Applied Medical Sciences, Jazan University. Subjects will be randomly assigned to into a heavy user group (n=300; female and male students) and a control or regular use group (n=300; female and male students) according to their smartphone addiction proneness scale.

Baseline hydraulic hand dynamometer: (Fabrication Enterprises Incorporated, White Plains,New York, USA) is used to measure the hand grip strength and pinch strength.

Algometer Commander (JTech Medical Company) is used on the location of the trigger point to assess the amount of pressure the patient could sustain before the patient registered the pressure as being painful for upper fiber of trapezius muscle and sternocleidomastoid muscle

Eligibility criteria: Inclusion Criteria:

1. The participant will be right-handed.
2. No abnormal findings confirmed through physical and neurological examination.
3. No congenital abnormalities in either the cervical or the lumbar spine.
4. No history of severe surgical procedures ( Park et al., 2015) .

Exclusion Criteria:

1. History of a neurological disease.
2. History of musculoskeletal injury of neck and lumbar region.
3. Unstable medical condition.

Primary outcomes:
measure: Pain pressure threshold for upper fiber of trapezius muscle
timeFrame: 3 minutes
measure: Pain pressure threshold for sternocleidomastoid muscle
timeFrame: 9 minutes
measure: Hand Grip Force
timeFrame: 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Riyadh
country: Saudi Arabia
facility: Jazan University
state: Jazan
Study officials:
References:
Clinical trial NCT06859320: Outcomes Of Laparoscopic Sleeve Gastrectomy In Patients With Hypothyroidism And Depression
Official title: Outcomes Of Laparoscopic Sleeve Gastrectomy In Patients With Hypothyroidism And Depression
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Obesity and Obesity-related Medical Conditions
Keywords: obesity
hypothyroidism
Depression
Lead sponsor: Zagazig University
Sponsor class: OTHER_GOV
First posted: 2025-03-05
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Sleeve gastrectomy (SG) continues to be one of the most popular bariatric procedures all over the world. It has been established that obesity is a predisposing factor for several comorbidities, including life-threatening conditions. Many studies have discussed the impact of sleeve gastrectomy on TSH level. But, since most obese patients have some sort of depression, we will try to study the impact of sleeve gastrectomy, depression and hypothyroidism on each other.


Eligibility criteria: Inclusion Criteria:

* obese patients with depression and hypothyroidism controlled by medical treatment candidate for sleeve gastrectomy

Exclusion Criteria:

* patients less than 18 or above 60
* other psychiatric or medical disorders.
* patients not fit for surgery
* un controlled patients

Primary outcomes:
measure: thyroid function tests
timeFrame: from one day to one year after surgery
measure: depression
timeFrame: from one day to one year after surgery
measure: weight
timeFrame: from one day to one year after surgery
measure: dose of thyroid replacement therapy
timeFrame: monthly from one day to one year post surgery.
measure: gasteric leakage
timeFrame: from one day to 1 week post-surgery
measure: wound infection
timeFrame: from one day to 2 weeks post-surgery
Secondary outcomes:
measure: age
timeFrame: 2 days pre-operative
measure: sex
timeFrame: 2 days pre-operative
measure: BMI ( Body Mass Index)
timeFrame: 2 days before surgery to one year after surgery
Other outcomes:
Locations:
city: Zagazig
country: Egypt
facility: Faculty of Medicine
state: Sharqia
city: Zagazig
country: Egypt
facility: Zagazig University Hospitals
Study officials:
References:
Clinical trial NCT00775320: Assessment of Suspected Intracranial Malignancy Using 3'-Deoxy-3'18 F-flourothymidine PET
Official title: Assessment of Suspected Intracranial Malignancy Using 3'-Deoxy-3'18 F-fluorothymidine Positron Emission Tomography
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Brain Tumor
Keywords: Brain scan
Lead sponsor: University of Oklahoma
Sponsor class: OTHER
Collaborators: name: Midwest Medical Isotopes
First posted: 2008-10-20
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Subjects diagnosed with a brain tumor and to undergo surgery

Brief summary: The primary objective of this study is to detect and quantify tumor cells of high grade malignant gliomas and metastatic brain lesions both before and after initial surgical resection in a cohort of newly diagnosed patients.

Detailed description: In this study, 35 patients will be selected to undergoing sequential imaging with FLT-PET. Prior to surgical resection, patients will undergo a preliminary FLT-PET. Additional FLT scans for a maximum of four scans.

Eligibility criteria: Inclusion Criteria:

* 18 years or older
* Women must not be pregnant or breast feeding
* Histologic or strong radiologic suspicion of high grade malignant glioma or ogliometastatic tumor(s)

Exclusion Criteria:

* May not have received previous therapy for their malignancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Oklahoma City
country: United States
facility: University Of Oklahoma Health Sciences Center
state: Oklahoma
Study officials:
affiliation: Assistant Professor
name: Jennifer Holter, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01153620: The Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds
Official title: Randomized, Double-blind, Controlled Clinical Trial on the Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Wounds
Keywords: Acute traumatic wounds
Lead sponsor: B. Braun Ltd. Centre of Excellence Infection Control
Sponsor class: INDUSTRY
First posted: 2010-06-30
Enrollment: 61
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The primary objective of the study is to assess the antiseptic efficacy of Lavasept 0.04% when used as an antiseptic agent and to compare these with Ringers' solution in patients with acute traumatic wounds.


Eligibility criteria: Inclusion Criteria:

* Patients with acute traumatic cut, crush, abrasion, bite or stab wounds Provision of voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent form approved by the Institutional Ethics Committee (IEC) prior to all evaluations
* Wounds that are a minimum of approximately 4 cm2 in size
* Ability to read and understand the German patient information sheet and informed consent form

Exclusion Criteria:

* \< 18 years of age
* Pregnancy
* Immunosuppression
* Wounds caused by a burn
* Wounds that require treatment of hyaline cartilage, the central nervous system, peritoneum, meningae, inner / middle ear or inner eye
* Simultaneous participation in another clinical trial
* Wounds that require immediate surgical or medical treatment as well patients who are critically ill
* Patient with a known allergy to the active agent or any of the excipients
* Wounds that are \>3 cm in depth
* Wounds that have not received medical treatment for ≥6 hours
* Heavily bleeding wounds
* Open fractures, joints or tendons
* Wounds of the face

Primary outcomes:
measure: Reduction (log10) in Colony Forming Units
timeFrame: 60 minutes
Secondary outcomes:
measure: Local Tolerability: Pruritis Burning
timeFrame: 60 minutes
measure: Reduction in CFU
timeFrame: 15 minutes, 30 minutes and 60 minutes
measure: Comparison of the Percentage of Patients With Target Wounds <50 CFU
timeFrame: 60 minutes
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital of Zurich
Study officials:
affiliation: University of Zurich
name: Hans Peter Simmen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04397120: The Factors Affecting ADR of Screening Colonoscopy
Official title: Comprehensive Analysis of Multilevel Factors Affecting Adenoma Detection Rates of Screening Colonoscopy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adenoma Detection Rate
Colonoscopy
Lead sponsor: The First Affiliated Hospital of Zhejiang Chinese Medical University
Sponsor class: OTHER
First posted: 2020-05-21
Enrollment: 13495
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Endoscopy Department of a university Hospital

Brief summary: The purpose of this study is to assess the impact of multilevel factors on the quality of screening colonoscopy, reflected mainly by adenoma detection rate (ADR).

Detailed description: The subjects will include patients who need to screening colonoscopies by 21 endoscopists between January 2019 and December 2019 were retrospectively enrolled in this unit. Multilevel factors, including patient-, proceduralist-, and procedure-level characteristics were analyzed for the relationship with ADR.

Eligibility criteria: Inclusion Criteria:

* Patients were retrospectively included in this study if they had undergone a completed colonoscopy.

Exclusion Criteria:

* prior colonoscopy within 3 years;
* medical history of inflammatory bowel disease (IBD), CRC, or abdominal surgery;
* fair or poor quality of bowel preparation (fair quality: some semisolid stool that could be suctioned or washed away but \>90% of mucosal surface seen; poor quality: semisolid stool that could not be suctioned or washed away with \<90% of mucosal surface seen);
* failure in cecal intubation;
* withdrawal time without removing\<6 min.

Primary outcomes:
measure: Adenoma detection rate
timeFrame: After histopathologically examined, reviewed, and confirmed, an average of 7 days.
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: First Affiliated Hospital of Zhejiang Chinese Medical University
state: Zhejiang
Study officials:
affiliation: First Affiliated Hospital of Zhejiang Chinese Medical University
name: Bin Lu, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07001020: Innovating Technology Solutions for Residents in Support Housing Communities w SUD Through Community-Engaged Research
Official title: Innovating Technology Solutions for Residents in Supportive Housing Communities With SUD Through Community-Engaged Research
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Housing Problems
Household Substance Abuse
Substance Use Disorders
Harm Reduction
Keywords: eviction, housing stability, training
Lead sponsor: Oregon Research Behavioral Intervention Strategies, Inc.
Sponsor class: INDUSTRY
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2025-06-03
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this clinical trial is to understand whether a technology-based solution, provided to residents in permanent supportive housing, is acceptable, feasible to implement, and has promise for improving resident stability. The main questions it aims to answer are:

• Is the technology-based, community-defined solution usable, acceptable, feasible, and have promise of effectiveness for improving resident knowledge?

There is no comparison group, all participants will receive the technology-based intervention. Researchers expect the intervention will include 2 weeks of intervention content that includes videos and incentives for completing content though the solution tested will ultimately be co-defined by our community board.

Detailed description: Our clinical trial is a pre-post assessment of resident knowledge.

Eligibility criteria: Residents:

1. 18 and older;
2. past or current resident in supportive housing community;
3. past or current elevated substance use

Staff:

1. 18 or older;
2. staff at partner agency

Primary outcomes:
measure: Knowledge
timeFrame: baseline; 30 days
measure: Self-efficacy
timeFrame: baseline; 30 days
measure: Behavioral intentions
timeFrame: baseline; 30 days
Secondary outcomes:
Other outcomes:
measure: Dosage
timeFrame: Through study completion, an average of 1 month
Locations:
city: Springfield
country: United States
facility: Oregon Research Behavioral Intervention Strategies, Inc.
state: Oregon
Study officials:
affiliation: Oregon Research Behavioral Intervention Strategies, Inc.
name: David R Smith, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05673720: Brain Stimulation and Meditation for Pain After Total Knee Arthroplasty
Official title: Feasibility, Acceptability, and Preliminary Efficacy of Combined Transcranial Direct Current Stimulation and Mindfulness for Pain After Total Knee Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoarthritis, Knee
Lead sponsor: Florida State University
Sponsor class: OTHER
First posted: 2023-01-06
Enrollment: 24
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Feasibility, acceptability, and preliminary efficacy of combined transcranial direct current stimulation and mindfulness for pain after total knee arthroplasty

Detailed description: The project is to assess the preliminary feasibility, acceptability, and efficacy of self-administered preoperative tDCS+MBI in older adults (50+) undergoing TKR. And to determine the effects of 5, 20-minute preoperative self-administered tDCS sessions combined with brief MBI on analgesic medication consumption following TKR.

Eligibility criteria: Inclusion Criteria:

* elective unilateral knee total replacement
* mentally capable of reading, giving consent and following instructions
* being able to answer questions in English
* not pregnant

Exclusion Criteria:

* history of brain surgery, brain tumor, seizure, stroke, or intracranial metal implantation
* systemic rheumatic disorders, including rheumatoid arthritis, systemic lupus erythematosus, and fibromyalgia
* alcohol/substance abuse
* current use of sodium channel blockers, calcium channel blockers and NMDS receptor antagonists
* hospitalization within the preceding year for psychiatric illness
* no access to a device with internet access that can be used for secure videoconferencing for real-time remote supervision

Primary outcomes:
measure: Analgesic consumption
timeFrame: day 3 after surgery
Secondary outcomes:
measure: numerical rating scale (NRS)
timeFrame: day 3 after surgery
measure: Brief Pain Inventory (BPI)
timeFrame: day 3 after surgery
measure: Patient Health Questionnaire-4 (PHQ-4)
timeFrame: day 3 after surgery
measure: Pain Catastrophizing Scale (PCS)
timeFrame: day 3 after surgery
measure: Change in pain related cortical response using a continuous wave, multichannel Functional near-infrared spectroscopy (fNIRS) imaging system
timeFrame: change from baseline at day 5 of intervention
measure: Change in descending pain modulation (CPM) as measured by the quantitative sensory testing
timeFrame: change from baseline at day 5 of intervention
Other outcomes:
Locations:
city: Tallahassee
country: United States
facility: Tallahassee Orthopedic Clinic
state: Florida
Study officials:
References:
Clinical trial NCT03316820: Bioavailability Study of K0706 in Healthy Subjects
Official title: A Randomized, Open Label, Four Period, Four Sequence, Single Dose, Crossover Study to Evaluate Relative Bioavailability of K0706 24 mg Tablet Formulation Relative to 24 mg Capsule Formulation Under Fasted Conditions and to Evaluate the Food Effect for Tablet Formulation in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Sun Pharma Advanced Research Company Limited
Sponsor class: INDUSTRY
First posted: 2017-10-20
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is single-center, single-dose, randomized, open-label, four-period, four sequence crossover study to evaluate the relative bioavailability of K0706 24 mg tablet formulation relative to 24 mg capsule formulation under fasted conditions and to evaluate the food-effect for tablet formulation in healthy subjects.


Eligibility criteria: Inclusion Criteria:

1. Willingness to provide written, informed consent for participation in the study in the compliance with the protocol requirements
2. Adult males or females aged between 18 and 55 years
3. Medically healthy on the basis of medical history and physical examination
4. Woman of childbearing potential must practice an acceptable method of birth control

Exclusion Criteria:

1. History of any major surgical or medical conditions within 4 weeks prior to dosing
2. History of blood transfusion and / or plasmapheresis within 4 weeks prior to dosing
3. Inability to swallow oral medication and / or difficulty to find peripheral access to veins or inability to undergo venipuncture
4. Any malignancy within the past 3 years (except for non-melanoma skin cancer or cervical cancer in situ)

Primary outcomes:
measure: Observed peak plasma concentration
timeFrame: 72 hours
Secondary outcomes:
measure: Adverse event
timeFrame: 26 days
Other outcomes:
Locations:
city: Las Vegas
country: United States
facility: SPARC Site 1
state: Nevada
Study officials:
References: